2 exciting penny stocks under 20p to consider buying today

Penny stocks aren’t for everyone. But for those comfortable with risk, they can be worth considering as returns can be substantial.

| More on:
Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny stocks tend to be risky investments. But they can generate spectacular returns at times, so they can be worth including in a diversified portfolio.

Here, I’m going to highlight two exciting penny stocks that I believe are worth a closer look today. Currently, both are trading for less than 20p.

High-risk, high-return

First up, we have Poolbeg Pharma (LSE: POLB). It’s an under-the-radar biopharmaceutical company that’s developing drugs (with the help of artificial intelligence) to address unmet medical needs.

Now, this is a classic penny stock in that it’s a high risk, high reward play. You see, this company doesn’t have any revenues or earnings at all today so it’s a very speculative investment.

But things could change. Currently, the company’s working on a range of drugs including products to treat cancer immunotherapy-induced Cytokine Release Syndrome (a condition that develops when an immune system responds too aggressively to infection) and obesity (it’s working on an oral weight-loss product).

If it was able to bring any of these drugs to the market, its revenues could explode. And so could its share price.

Of course, investors shouldn’t assume successful market launches will happen. Drug development’s a notoriously challenging industry in which major setbacks are the norm.

I see a lot of potential here though. I think Poolbeg Pharma’s worth considering as a speculative investment.

A high-growth industry

The other penny stock I want to highlight today is Corero Network Security (LSE: CNS). It’s a small cybersecurity company that specialises in Distributed Denial of Service (DDoS) protection solutions.

I see this stock as a little less risky than Poolbeg Pharma. That’s because the company already has revenues. Last year, these came in at $22.3m. This year, analysts expect $28m (growth of an impressive 26%).

That said, it’s still a very risky stock as the company’s profits are small. For 2024, net profit and earnings per share are only expected to come in at around $375,000 and 0.1 cents respectively.

Again though, I’m excited about the potential here. Cybersecurity’s a rapidly growing industry and this company’s having a lot of success at present, having recently signed a number of contacts with firms of different shapes and sizes.

If it can continue to do this and grow its revenues and earnings in the years ahead, I think it could turn out to be a decent investment. It’s worth noting that in July, the company said that it continues to experience high demand for its SmartWall ONETM DDoS protection solutions and that its pipeline is at record levels.

Of course, cybercrime’s always evolving. So there’s guarantee this company will continue to be successful going forward.

As a speculative investment however, I believe it’s worth a look.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Micro-Cap Shares

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

Penny stocks with promise! Could one of these little UK tech companies be the next big thing? 

I'm considering the prospects of two lesser-known telecoms penny stocks that are undervalued and have lots of growth potential.

Read more »

A young Asian woman holding up her index finger
Investing Articles

1 almost penny stock I’d buy if stock markets start to dip

When the stock market starts to tumble, I won’t be panicking. Instead, I’ll be snapping up some dirt cheap penny…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Is this 13p penny stock the next gem for my Stocks and Shares ISA?

This promising penny stock is undervalued and appears to be on track to make gains in the coming years. Should…

Read more »

Micro-Cap Shares

Should I follow Hargreaves Lansdown investors and buy 1.3p penny stock Helium One Global?

Hargreaves Lansdown investors have been piling into a penny stock that currently trades for just over 1p. Should Edward Sheldon…

Read more »

Investing Articles

Cheap penny stocks to consider buying in September

I keep looking at my top penny stocks, and I keep finding they've climbed and I missed them. But there…

Read more »